New CEO takes helm at UK's BioProgress

Related tags Vice president Senior vice president Management occupations

BioProgress has appointed Richard Trevillion as chief
executive, bolstering its executive management just over a month
after the dosage film specialist issued a trading statement that
sparked a 40 per cent slump in its UK-listed shares, which prompted
the resignantion of former CEO Graham Hind.

Trevilion has been acting as interim CEO since the end of April, shortly after BioProgress issued a statement indicating that sales at its US subsidiary BioTec Films were not as strong as previously anticipated and are unlikely to reach levels indicated in previous announcements. An ongoing financial and strategic review of the business will be completed by the end of this month.

Meanwhile, other appointments of note in the pharmaceutical sector include the following announcements.

Abgenix​, a biopharmaceutical company focused on development of antibody therapeutics, has appointed Marc Better​ as vice president of process sciences. He was formerly VP, technical development, at XOMA, responsible for process development and clinical manufacturing operations in the XOMA pilot facility.

John Gordon​ has joined Millipore​ as corporate VP of worldwide human resources, reporting directly to CEO, chairman and president Martin Madaus.

Nanotechnology company pSivida said that its wholly owned subsidiary AION Diagnostics​ has appointed Dr Joerg Schreiber​ as a non-executive director. Schreiber has over 20 years experience in the diagnostics industry whilst working with a global leader in the sector. Dr. Schreiber joined Roche Diagnostics in 1986 following the merger of Boehringer Mannheim in Germany, and during this time held key senior roles including Vice President for R&D and Special Projects in the US, until his recent retirement.

Cardinal Health​ has named Eric Slusser​ to the newly created position of senior vice president of finance, chief accounting officer and controller, reporting to Jeff Henderson, Cardinal Health's chief financial officer. Since November 2003, Slusser has been senior vice president and corporate controller at MCI.

Microfluidics specialist Nanostream​ has promoted Hau Duong​ to the post of VP, engineering. Dr Duong has over 18 years of experience in instrumentation development and customer support for analytical systems ranging from DNA-based medical devices to thermonuclear fusion diagnostics.

US generics company Mylan Laboratories​ has appointed John Deiriggi​ to the new position of VP of generic business development, and named Hal Korman​ president of Mylan Pharmaceuticals.

US firm BioMarin Pharmaceuticals​ has recruited Jean-Jacques Bienaime​ as its CEO. He was most recently chairman, CEO and president of Genencor International.

Amgen​, the world's largest biotechnology firm, has promoted Jim Daly​ to the new position of senior vice president, North America commercial operations. Mr Daly was previously VP and general manager of the group's oncology business unit.

Related topics Markets & Regulations